ANDA 206516, held by Actavis LLC. Levoleucovorin Calcium.
As of Nov 16, 2026, ANDA 206516 (Levoleucovorin Calcium), held by Actavis LLC, was first approved by FDA on Feb 13, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 13, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levoleucovorin CalciumEQ 50MG BASE/VIAL ยท powder;intravenous | Levoleucovorin Calcium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters